[{"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-001", "question": "A 54-year-old man with decompensated alcoholic cirrhosis (MELD-Na 29) is intubated for acute variceal hemorrhage and started on norepinephrine for hemorrhagic shock. Despite volume resuscitation, blood products, and endoscopic band ligation, he requires increasing vasopressor doses. Continuous renal replacement therapy is initiated for worsening azotemia and hyperkalemia. His MAP is 62 mm Hg on norepinephrine 0.24 mcg/kg/min and vasopressin 0.03 units/min. Lactate is 5.1 mmol/L; pH 7.28; ScvO2 76%. Bedside echo shows hyperdynamic LV function, small underfilled LV, and collapsible IVC. CVP is 4 mm Hg. You are considering adding a third agent. Which vasopressor strategy is most appropriate now?", "options": ["Add epinephrine infusion targeting higher MAP (70-75 mm Hg)", "Add low-dose dobutamine to improve splanchnic perfusion", "Add angiotensin II infusion while maintaining current MAP target", "Increase vasopressin above 0.04 units/min to exploit V1 receptor effect", "Switch norepinephrine to phenylephrine to minimize beta-adrenergic effects"], "answer": "C", "answer_index": 2, "explanation": "He has vasodilatory shock in advanced cirrhosis with catecholamine-resistant hypotension despite adequate volume; angiotensin II is reasonable as a third-line agent in catecholamine-refractory vasodilatory shock and has emerging use in hepatorenal-type circulatory failure. Epinephrine would increase lactate and myocardial oxygen demand without addressing RAAS dysregulation; high-dose vasopressin increases ischemia risk, phenylephrine may worsen gut perfusion, and dobutamine is not indicated with hyperdynamic LV and adequate ScvO2.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes catecholamine-refractory vasodilatory shock in decompensated cirrhosis (MELD-Na 29, variceal hemorrhage, on dual vasopressors with inadequate MAP despite volume resuscitation). Key discriminating findings: hyperdynamic LV, underfilled ventricle, collapsible IVC, low CVP (4 mmHg), elevated lactate (5.1), acidosis, adequate ScvO2 (76%), requiring escalating vasopressor support. This represents distributive shock with preserved cardiac output but profound vasodilation. Option C (angiotensin II) is the most defensible third-line agent for catecholamine-resistant vasodilatory shock, particularly in cirrhosis where RAAS dysregulation contributes to pathophysiology. Option A (epinephrine) would increase lactate and myocardial oxygen demand without addressing underlying vasodilation. Option B (dobutamine) is inappropriate given hyperdynamic function and adequate ScvO2. Option D (high-dose vasopressin >0.04 units/min) increases ischemic complications without proven benefit. Option E (phenylephrine) lacks beta-agonism and may worsen splanchnic perfusion. Medical accuracy: Angiotensin II use in catecholamine-refractory shock is supported by ATHOS-3 trial data and emerging literature in cirrhotic shock. The physiologic reasoning is sound. Minimal fix: None required; item is logically valid and medically accurate.\", \"medical_accuracy_score\": \"4\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes catecholamine-refractory vasodilatory shock in decompensated cirrhosis (MELD-Na 29, variceal hemorrhage, on dual vasopressors with inadequate MAP despite volume resuscitation). Key discriminating findings: hyperdynamic LV, underfilled ventricle, collapsible IVC, low CVP (4 mmHg), elevated lactate (5.1), acidosis, adequate ScvO2 (76%), requiring escalating vasopressor support. This represents distributive shock with preserved cardiac output but profound vasodilation. Option C (angiotensin II) is the most defensible third-line agent for catecholamine-resistant vasodilatory shock, particularly in cirrhosis where RAAS dysregulation contributes to pathophysiology. Option A (epinephrine) would increase lactate and myocardial oxygen demand without addressing underlying vasodilation. Option B (dobutamine) is inappropriate given hyperdynamic function and adequate ScvO2. Option D (high-dose vasopressin >0.04 units/min) increases ischemic complications without proven benefit. Option E (phenylephrine) lacks beta-agonism and may worsen splanchnic perfusion. Medical accuracy: Angiotensin II use in catecholamine-refractory shock is supported by ATHOS-3 trial data and emerging literature in cirrhotic shock. The physiologic reasoning is sound. Minimal fix: None required; item is logically valid and medically accurate.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-002", "question": "A 63-year-old woman with a history of JAK2-positive polycythemia vera treated with hydroxyurea for 9 years presents with 3 months of progressive fatigue, 7-kg weight loss, early satiety, and drenching night sweats. Exam shows marked splenomegaly 12 cm below the costal margin. CBC: Hgb 9.1 g/dL, MCV 96 fL, WBC 18,000/µL with left shift, platelets 110,000/µL. Peripheral smear reveals tear-drop cells, nucleated RBCs, and leukoerythroblastosis. LDH is elevated; uric acid is high. Bone marrow aspirate is 'dry'; core biopsy shows hypercellular marrow with grade 3 reticulin fibrosis and atypical megakaryocytic clusters. Cytogenetics: new complex karyotype with monosomy 7. Which is the most appropriate next step in disease-directed management?", "options": ["Escalate hydroxyurea dose and add low-dose aspirin", "Start ruxolitinib and defer further planning until spleen size stabilizes", "Proceed to allogeneic hematopoietic stem cell transplantation evaluation", "Begin azacitidine as first-line therapy for post-PV myelofibrosis", "Initiate weekly pegylated interferon alfa-2a for cytoreduction"], "answer": "C", "answer_index": 2, "explanation": "She has post-polycythemia vera myelofibrosis with symptomatic splenomegaly, cytopenias, leukoerythroblastosis, and high-risk features (complex karyotype, monosomy 7), making allogeneic stem cell transplantation the only curative option and the preferred strategy if eligible. Ruxolitinib improves symptoms and spleen size but is not curative; azacitidine and interferon are not standard first-line disease-modifying therapies in high-risk post-PV MF, and hydroxyurea escalation will not address progression.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 63-year-old woman with JAK2+ polycythemia vera on hydroxyurea for 9 years who now presents with constitutional symptoms, massive splenomegaly, cytopenias, leukoerythroblastosis, tear-drop cells, dry tap, grade 3 reticulin fibrosis, and critically—a new complex karyotype with monosomy 7. This constellation definitively indicates transformation to post-PV myelofibrosis with high-risk features. Key discriminating findings: complex cytogenetics (monosomy 7) confers very high risk per DIPSS-plus/MIPSS70+ scoring systems, making this patient a candidate for curative therapy if medically fit. Option C (allogeneic HSCT evaluation) is the only potentially curative approach and is standard of care for transplant-eligible high-risk MF patients. Option B (ruxolitinib) is palliative, not curative. Option D (azacitidine) lacks established efficacy as first-line disease-modifying therapy in post-PV MF. Options A and E do not address high-risk disease biology. The stem provides sufficient detail (age, performance status implied by presentation, high-risk cytogenetics) to justify transplant evaluation as the most appropriate next step. No logical flaws or medical inaccuracies detected. Minimal fix: None needed; item is valid and accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 63-year-old woman with JAK2+ polycythemia vera on hydroxyurea for 9 years who now presents with constitutional symptoms, massive splenomegaly, cytopenias, leukoerythroblastosis, tear-drop cells, dry tap, grade 3 reticulin fibrosis, and critically—a new complex karyotype with monosomy 7. This constellation definitively indicates transformation to post-PV myelofibrosis with high-risk features. Key discriminating findings: complex cytogenetics (monosomy 7) confers very high risk per DIPSS-plus/MIPSS70+ scoring systems, making this patient a candidate for curative therapy if medically fit. Option C (allogeneic HSCT evaluation) is the only potentially curative approach and is standard of care for transplant-eligible high-risk MF patients. Option B (ruxolitinib) is palliative, not curative. Option D (azacitidine) lacks established efficacy as first-line disease-modifying therapy in post-PV MF. Options A and E do not address high-risk disease biology. The stem provides sufficient detail (age, performance status implied by presentation, high-risk cytogenetics) to justify transplant evaluation as the most appropriate next step. No logical flaws or medical inaccuracies detected. Minimal fix: None needed; item is valid and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-003", "question": "A 28-year-old G1P0 woman at 33 weeks' gestation presents to the ED with acute dyspnea, pleuritic chest pain, and near syncope. HR 132/min, BP 82/48 mm Hg, RR 30/min, SpO2 89% on 6 L nasal cannula. Bedside echo reveals a dilated RV with McConnell sign and septal flattening. CTA is unavailable; lower-extremity duplex is pending. She is consentable and has no contraindications to thrombolysis. Fetal heart tones are 150 bpm with moderate variability. Which management is most appropriate now?", "options": ["Systemic thrombolysis with weight-based alteplase bolus and infusion", "Urgent catheter-directed thrombolysis with reduced-dose alteplase", "Immediate transfer for surgical embolectomy with cardiopulmonary bypass", "Initiate high-dose unfractionated heparin and defer reperfusion until postpartum", "Administer tenecteplase as a single IV bolus followed by heparin"], "answer": "A", "answer_index": 0, "explanation": "She has high-risk (massive) pulmonary embolism with shock in late pregnancy; systemic thrombolysis is recommended when no absolute contraindications exist, as maternal survival takes priority and pregnancy is only a relative contraindication. Catheter-directed therapy or surgical embolectomy may be considered when thrombolysis is contraindicated or fails, not as first-line; deferring reperfusion is unsafe, and tenecteplase bolus lacks robust pregnancy-specific safety and dosing data compared with standard alteplase protocols.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict: Correct best answer. The vignette describes a 33-week pregnant woman with massive PE (shock: BP 82/48, HR 132, hypoxemia despite O2, RV dysfunction with McConnell sign). Key discriminating findings are hemodynamic instability (massive/high-risk PE) plus pregnancy at 33 weeks with no stated contraindications to thrombolysis. Standard guidelines (ESC, AHA) classify this as high-risk PE requiring reperfusion; systemic thrombolysis is first-line when no absolute contraindications exist. Pregnancy is a relative contraindication, but maternal life-threatening shock overrides fetal risk. Option A (systemic alteplase) is guideline-concordant first-line therapy. Option B (catheter-directed) is reserved for contraindications or failure of systemic lysis. Option C (surgical embolectomy) is for thrombolysis failure/contraindication or cardiac arrest. Option D (heparin alone) is inadequate for massive PE with shock. Option E (tenecteplase) lacks robust pregnancy-specific data compared to alteplase. The item is logically valid: one defensible best answer matching the key. Medical accuracy is high; aligns with current PE guidelines prioritizing maternal survival. Minimal fix: None needed; item is unambiguous and accurate.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 33-week pregnant woman with massive PE (shock: BP 82/48, HR 132, hypoxemia despite O2, RV dysfunction with McConnell sign). Key discriminating findings are hemodynamic instability (massive/high-risk PE) plus pregnancy at 33 weeks with no stated contraindications to thrombolysis. Standard guidelines (ESC, AHA) classify this as high-risk PE requiring reperfusion; systemic thrombolysis is first-line when no absolute contraindications exist. Pregnancy is a relative contraindication, but maternal life-threatening shock overrides fetal risk. Option A (systemic alteplase) is guideline-concordant first-line therapy. Option B (catheter-directed) is reserved for contraindications or failure of systemic lysis. Option C (surgical embolectomy) is for thrombolysis failure/contraindication or cardiac arrest. Option D (heparin alone) is inadequate for massive PE with shock. Option E (tenecteplase) lacks robust pregnancy-specific data compared to alteplase. The item is logically valid: one defensible best answer matching the key. Medical accuracy is high; aligns with current PE guidelines prioritizing maternal survival. Minimal fix: None needed; item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-004", "question": "A 4-year-old boy is brought to the PICU with progressive leg weakness and refusal to walk for 5 days after a viral upper respiratory infection. Exam: flaccid symmetric weakness in legs > arms, areflexia, intact sensation, no bowel/bladder dysfunction, and no cranial nerve involvement. He can lift his head briefly but cannot stand; FVC is 55% predicted. MRI spine is normal. CSF shows protein 42 mg/dL, 3 WBC/µL. Nerve conduction studies show reduced CMAP amplitudes with preserved conduction velocities and distal latencies; sensory studies are normal, and F-waves are absent. Which subtype best describes his neuropathy and has implications for prognosis and treatment response?", "options": ["Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)", "Acute motor axonal neuropathy (AMAN) variant of Guillain-Barré syndrome", "Acute motor and sensory axonal neuropathy (AMSAN)", "Miller Fisher syndrome", "Acute flaccid myelitis related to enterovirus D68"], "answer": "B", "answer_index": 1, "explanation": "Normal conduction velocities with low CMAP amplitudes, preserved sensory responses, and absent F-waves indicate a purely motor axonal process, characteristic of AMAN, which in children often follows infection and may have rapid progression but good recovery with immunotherapy. AIDP would show demyelinating features (slowed velocities, prolonged latencies), AMSAN would have sensory involvement, Miller Fisher presents with ophthalmoplegia/ataxia, and acute flaccid myelitis involves spinal gray matter with MRI abnormalities and asymmetric weakness.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 4-year-old with acute flaccid paralysis post-viral infection. Key discriminating findings: (1) symmetric flaccid weakness legs>arms, (2) areflexia, (3) intact sensation, (4) normal MRI spine, (5) CSF with albuminocytologic dissociation (protein 42 mg/dL, 3 WBC), (6) NCS showing reduced CMAP amplitudes with preserved conduction velocities/distal latencies, (7) normal sensory studies, (8) absent F-waves. These findings point to pure motor axonal neuropathy. The keyed answer (B, AMAN) correctly matches: preserved conduction velocities with reduced amplitudes indicate axonal loss rather than demyelination; purely motor involvement with normal sensory studies; absent F-waves support proximal motor axon dysfunction. Alternative assessment: (A) AIDP would show demyelinating features—slowed velocities, prolonged latencies—not present here. (C) AMSAN requires sensory involvement, explicitly absent. (D) Miller Fisher presents with ophthalmoplegia/ataxia/areflexia, not mentioned. (E) AFM typically shows asymmetric weakness and MRI abnormalities in spinal gray matter, both absent. The item is logically valid with one defensible best answer. Medical accuracy is high; AMAN diagnosis and NCS criteria are standard. Minimal fix: None needed; item is well-constructed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 4-year-old with acute flaccid paralysis post-viral infection. Key discriminating findings: (1) symmetric flaccid weakness legs>arms, (2) areflexia, (3) intact sensation, (4) normal MRI spine, (5) CSF with albuminocytologic dissociation (protein 42 mg/dL, 3 WBC), (6) NCS showing reduced CMAP amplitudes with preserved conduction velocities/distal latencies, (7) normal sensory studies, (8) absent F-waves. These findings point to pure motor axonal neuropathy. The keyed answer (B, AMAN) correctly matches: preserved conduction velocities with reduced amplitudes indicate axonal loss rather than demyelination; purely motor involvement with normal sensory studies; absent F-waves support proximal motor axon dysfunction. Alternative assessment: (A) AIDP would show demyelinating features—slowed velocities, prolonged latencies—not present here. (C) AMSAN requires sensory involvement, explicitly absent. (D) Miller Fisher presents with ophthalmoplegia/ataxia/areflexia, not mentioned. (E) AFM typically shows asymmetric weakness and MRI abnormalities in spinal gray matter, both absent. The item is logically valid with one defensible best answer. Medical accuracy is high; AMAN diagnosis and NCS criteria are standard. Minimal fix: None needed; item is well-constructed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-005", "question": "A 47-year-old man with poorly controlled type 2 diabetes and daily alcohol use presents with 10 days of fever, right-sided headache, and progressive confusion. He was treated with oral amoxicillin-clavulanate for presumed sinusitis without improvement. On exam he is disoriented, febrile (38.8°C), with mild left hemiparesis and papilledema. CT head with contrast shows a 3.5-cm ring-enhancing lesion in the right frontal lobe with extensive surrounding edema contiguous with opacified frontal sinus. Emergent dexamethasone and broad-spectrum IV antibiotics are started. Neurocritical care team plans operative management. Which surgical approach is most appropriate now?", "options": ["CT-guided stereotactic needle aspiration of the abscess", "Open craniotomy with complete abscess excision and sinus drainage", "Endoscopic transnasal drainage of the frontal sinus only", "Placement of an external ventricular drain for CSF diversion and observation", "Delay surgical intervention; continue maximal medical therapy for 2 weeks"], "answer": "B", "answer_index": 1, "explanation": "A large frontal lobe abscess contiguous with frontal sinus and mass effect in an immunocompromised host favors open craniotomy with abscess excision plus definitive sinus drainage to eradicate the source and relieve mass effect. Needle aspiration alone risks persistent infection from ongoing sinus seeding; sinus drainage only is insufficient; EVD does not address the mass; delaying surgery risks herniation and neurological decline.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 47-year-old immunocompromised patient (poorly controlled diabetes, alcohol use) with a large (3.5-cm) ring-enhancing frontal lobe abscess contiguous with opacified frontal sinus, presenting with mass effect (papilledema, hemiparesis, confusion) despite oral antibiotics. Key discriminating findings: (1) large abscess >2.5 cm, (2) significant mass effect with neurological deterioration, (3) direct contiguity with infected sinus source, (4) immunocompromised host, (5) failed medical therapy. These factors favor aggressive surgical intervention. Option B (open craniotomy with complete excision plus sinus drainage) addresses both the intracranial collection and the ongoing source, appropriate for large abscesses with mass effect in high-risk patients. Option A (needle aspiration) is inadequate for this size and leaves the sinus source untreated. Option C addresses only the sinus, not the established brain abscess. Option D (EVD) treats hydrocephalus but not the mass lesion. Option E (delay) risks herniation given existing mass effect. The keyed answer aligns with neurosurgical principles for large, symptomatic brain abscesses with identifiable sources. No logical flaws or medical inaccuracies detected. Minimal fix: none needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 47-year-old immunocompromised patient (poorly controlled diabetes, alcohol use) with a large (3.5-cm) ring-enhancing frontal lobe abscess contiguous with opacified frontal sinus, presenting with mass effect (papilledema, hemiparesis, confusion) despite oral antibiotics. Key discriminating findings: (1) large abscess >2.5 cm, (2) significant mass effect with neurological deterioration, (3) direct contiguity with infected sinus source, (4) immunocompromised host, (5) failed medical therapy. These factors favor aggressive surgical intervention. Option B (open craniotomy with complete excision plus sinus drainage) addresses both the intracranial collection and the ongoing source, appropriate for large abscesses with mass effect in high-risk patients. Option A (needle aspiration) is inadequate for this size and leaves the sinus source untreated. Option C addresses only the sinus, not the established brain abscess. Option D (EVD) treats hydrocephalus but not the mass lesion. Option E (delay) risks herniation given existing mass effect. The keyed answer aligns with neurosurgical principles for large, symptomatic brain abscesses with identifiable sources. No logical flaws or medical inaccuracies detected. Minimal fix: none needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-006", "question": "A 66-year-old man with COPD and metastatic non-small cell lung cancer (PD-L1 80%) started pembrolizumab 10 weeks ago. He presents with 4 days of worsening exertional dyspnea and dry cough, afebrile, with O2 saturation 90% on room air. CT pulmonary angiography shows no embolus but reveals new bilateral, patchy ground-glass opacities and reticular changes in the lower lobes with subpleural sparing. There is no infection on extensive workup, BNP is normal, and no cardiac ischemia. He is on no new drugs besides pembrolizumab. How should this complication be graded and managed now?", "options": ["Grade 1 pneumonitis; continue pembrolizumab with close monitoring only", "Grade 2 pneumonitis; hold pembrolizumab and start prednisone 0.5 mg/kg/day", "Grade 2 pneumonitis; hold pembrolizumab and start prednisone 1-2 mg/kg/day", "Grade 3 pneumonitis; permanently discontinue pembrolizumab and give IV methylprednisolone 1-2 mg/kg/day", "Grade 3 pneumonitis; permanently discontinue pembrolizumab and give infliximab immediately without steroids"], "answer": "C", "answer_index": 2, "explanation": "He has symptomatic but non-life-threatening immune-related pneumonitis (dyspnea, new infiltrates, no severe hypoxia), corresponding to grade 2; standard management is to hold the checkpoint inhibitor and start systemic steroids at 1-2 mg/kg/day with a prolonged taper. Grade 3 would involve severe symptoms or oxygen requirement; lower steroid doses or continuation of pembrolizumab are inadequate, and infliximab is reserved for steroid-refractory cases, not first-line.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 66-year-old man on pembrolizumab presenting with exertional dyspnea, dry cough, O2 sat 90% on room air, and bilateral ground-glass opacities on CT with no alternative etiology (no PE, infection, cardiac cause). Key discriminating findings: symptomatic dyspnea with hypoxemia (90% O2 sat) requiring supplemental oxygen consideration, new radiographic changes, temporal relationship to checkpoint inhibitor (10 weeks post-initiation), and exclusion of other causes. This constellation indicates immune-related pneumonitis. Grading: Grade 2 pneumonitis is defined as symptomatic with new radiographic findings and mild-moderate hypoxemia (typically O2 sat 88-94% or requiring <4L O2), not life-threatening. Grade 3 requires severe symptoms with limiting ADLs or O2 sat <88% or >4L O2 requirement. This patient's O2 sat of 90% with exertional dyspnea fits Grade 2. Management: Grade 2 pneumonitis requires holding the checkpoint inhibitor and initiating prednisone 1-2 mg/kg/day, not 0.5 mg/kg (insufficient). Grade 3 would require permanent discontinuation and IV steroids. Option A underestimates severity. Option B uses inadequate steroid dosing. Options D-E overgrade the severity. No logical flaws or medical inaccuracies present. Minimal fix: None needed; item is valid.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 66-year-old man on pembrolizumab presenting with exertional dyspnea, dry cough, O2 sat 90% on room air, and bilateral ground-glass opacities on CT with no alternative etiology (no PE, infection, cardiac cause). Key discriminating findings: symptomatic dyspnea with hypoxemia (90% O2 sat) requiring supplemental oxygen consideration, new radiographic changes, temporal relationship to checkpoint inhibitor (10 weeks post-initiation), and exclusion of other causes. This constellation indicates immune-related pneumonitis. Grading: Grade 2 pneumonitis is defined as symptomatic with new radiographic findings and mild-moderate hypoxemia (typically O2 sat 88-94% or requiring <4L O2), not life-threatening. Grade 3 requires severe symptoms with limiting ADLs or O2 sat <88% or >4L O2 requirement. This patient's O2 sat of 90% with exertional dyspnea fits Grade 2. Management: Grade 2 pneumonitis requires holding the checkpoint inhibitor and initiating prednisone 1-2 mg/kg/day, not 0.5 mg/kg (insufficient). Grade 3 would require permanent discontinuation and IV steroids. Option A underestimates severity. Option B uses inadequate steroid dosing. Options D-E overgrade the severity. No logical flaws or medical inaccuracies present. Minimal fix: None needed; item is valid.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-007", "question": "A 9-year-old girl presents with 2 weeks of progressive headache, morning vomiting, and decline in school performance. Exam reveals papilledema, dysmetria, and truncal ataxia. MRI brain shows an enhancing midline posterior fossa mass infiltrating the cerebellar vermis and roof of the fourth ventricle, with obstructive hydrocephalus. After CSF diversion and near-total resection, histology shows small round blue cells with Homer-Wright rosettes. Molecular profiling reveals WNT-activated medulloblastoma, CTNNB1 mutation, and monosomy 6; no metastatic disease on staging. Which adjuvant treatment strategy is most appropriate?", "options": ["Craniospinal irradiation at standard dose plus multi-agent chemotherapy (high-risk protocol)", "Focal posterior fossa irradiation only plus maintenance oral temozolomide", "Reduced-dose craniospinal irradiation with posterior fossa boost plus chemotherapy (standard-risk protocol)", "Observation only after gross total resection due to favorable WNT subtype", "High-dose chemotherapy with autologous stem cell rescue, without craniospinal irradiation"], "answer": "C", "answer_index": 2, "explanation": "WNT-activated medulloblastoma in a child with non-metastatic disease and near-total resection is standard-risk; current practice uses reduced-dose craniospinal irradiation with posterior fossa boost plus multi-agent chemotherapy to maintain excellent survival while reducing late toxicity. Standard-dose/high-risk protocols are unnecessary; focal RT alone or observation is inadequate due to CSF dissemination risk; high-dose chemo without CSI is investigational and not standard in this scenario.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 9-year-old with classic posterior fossa medulloblastoma (headache, morning vomiting, papilledema, cerebellar signs, midline vermis mass, obstructive hydrocephalus, Homer-Wright rosettes). Key discriminating findings: WNT-activated subtype with CTNNB1 mutation and monosomy 6, near-total resection, no metastatic disease, age >3 years. WNT-subgroup medulloblastoma has excellent prognosis (>95% survival) and is classified as standard-risk even with M0 disease and near-total resection. Current standard of care per COG and international protocols is reduced-dose craniospinal irradiation (23.4 Gy vs 36 Gy) with posterior fossa boost plus chemotherapy to minimize late neurocognitive and endocrine toxicity while maintaining cure rates. Option C correctly matches this approach. Option A (high-risk protocol with standard-dose CSI) is medically inappropriate—overtreats favorable-risk disease. Option B (focal RT only) inadequately addresses CSF dissemination risk. Option D (observation) contradicts standard practice requiring adjuvant therapy. Option E (chemo without CSI) is investigational only. The item is logically valid with one defensible best answer matching the key. Medical accuracy is excellent, reflecting current risk-stratified medulloblastoma management. Minimal fix: none needed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 9-year-old with classic posterior fossa medulloblastoma (headache, morning vomiting, papilledema, cerebellar signs, midline vermis mass, obstructive hydrocephalus, Homer-Wright rosettes). Key discriminating findings: WNT-activated subtype with CTNNB1 mutation and monosomy 6, near-total resection, no metastatic disease, age >3 years. WNT-subgroup medulloblastoma has excellent prognosis (>95% survival) and is classified as standard-risk even with M0 disease and near-total resection. Current standard of care per COG and international protocols is reduced-dose craniospinal irradiation (23.4 Gy vs 36 Gy) with posterior fossa boost plus chemotherapy to minimize late neurocognitive and endocrine toxicity while maintaining cure rates. Option C correctly matches this approach. Option A (high-risk protocol with standard-dose CSI) is medically inappropriate—overtreats favorable-risk disease. Option B (focal RT only) inadequately addresses CSF dissemination risk. Option D (observation) contradicts standard practice requiring adjuvant therapy. Option E (chemo without CSI) is investigational only. The item is logically valid with one defensible best answer matching the key. Medical accuracy is excellent, reflecting current risk-stratified medulloblastoma management. Minimal fix: none needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-008", "question": "A 71-year-old woman with hypertension and atrial fibrillation on rivaroxaban is admitted with sudden onset aphasia and right hemiplegia. CT head is negative for hemorrhage; CTA shows left M1 occlusion. Last rivaroxaban dose was 3 hours ago. Labs: creatinine 0.9 mg/dL, normal platelets, INR 1.2, anti-factor Xa level (rivaroxaban-calibrated) 170 ng/mL. She arrives 70 minutes after symptom onset. You are in a center with neurointerventional capability and access to andexanet alfa and 4-factor PCC. What is the best acute reperfusion strategy?", "options": ["Administer IV alteplase followed by mechanical thrombectomy", "Administer andexanet alfa to reverse rivaroxaban, then give IV alteplase", "Proceed directly to mechanical thrombectomy without IV thrombolysis", "Give 4-factor PCC then IV alteplase to offset rivaroxaban effect", "Defer reperfusion therapy and manage with permissive hypertension alone"], "answer": "C", "answer_index": 2, "explanation": "Recent rivaroxaban ingestion with high anti-factor Xa level is a contraindication to IV alteplase, and reversal with andexanet or PCC before tPA is not recommended due to uncertain safety and lack of evidence. In patients with large-vessel occlusion on DOACs, direct mechanical thrombectomy is the preferred reperfusion strategy. Withholding reperfusion altogether is inappropriate given eligibility for thrombectomy.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 71-year-old woman with acute ischemic stroke (aphasia, right hemiplegia) presenting within the thrombolysis window (70 minutes) with confirmed left M1 occlusion on CTA. Key discriminating findings: (1) recent rivaroxaban dose 3 hours ago with elevated anti-factor Xa level (170 ng/mL), (2) large-vessel occlusion (LVO) amenable to mechanical thrombectomy, (3) comprehensive stroke center capability. The keyed answer (C, direct mechanical thrombectomy) is defensible because: recent DOAC use with measurable drug levels contraindicates IV alteplase per current guidelines; reversal agents before tPA lack safety/efficacy data and are not recommended; mechanical thrombectomy alone is standard for LVO in DOAC patients. Alternative assessment: A is contraindicated (alteplase with active DOAC); B/D lack evidence and add thrombotic risk from reversal agents; E inappropriately withholds proven therapy. No logical flaws exist—the stem provides sufficient detail (timing, drug levels, imaging, capabilities) to select one best answer. Medical accuracy is high: aligns with AHA/ASA stroke guidelines and recent trials showing mechanical thrombectomy efficacy in DOAC patients without thrombolysis. Minimal fix: none needed; item is valid and accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 71-year-old woman with acute ischemic stroke (aphasia, right hemiplegia) presenting within the thrombolysis window (70 minutes) with confirmed left M1 occlusion on CTA. Key discriminating findings: (1) recent rivaroxaban dose 3 hours ago with elevated anti-factor Xa level (170 ng/mL), (2) large-vessel occlusion (LVO) amenable to mechanical thrombectomy, (3) comprehensive stroke center capability. The keyed answer (C, direct mechanical thrombectomy) is defensible because: recent DOAC use with measurable drug levels contraindicates IV alteplase per current guidelines; reversal agents before tPA lack safety/efficacy data and are not recommended; mechanical thrombectomy alone is standard for LVO in DOAC patients. Alternative assessment: A is contraindicated (alteplase with active DOAC); B/D lack evidence and add thrombotic risk from reversal agents; E inappropriately withholds proven therapy. No logical flaws exist—the stem provides sufficient detail (timing, drug levels, imaging, capabilities) to select one best answer. Medical accuracy is high: aligns with AHA/ASA stroke guidelines and recent trials showing mechanical thrombectomy efficacy in DOAC patients without thrombolysis. Minimal fix: none needed; item is valid and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-009", "question": "A 22-year-old man with sickle cell disease (HbSS) presents with high fever, cough, and pleuritic chest pain. CXR shows new multilobar infiltrates; oxygen saturation is 93% on 2 L/min nasal cannula. Labs: Hgb 7.2 g/dL (baseline 8.5), WBC 18,000/µL, platelets 310,000/µL, reticulocyte count 12%. He is diagnosed with acute chest syndrome and started on broad-spectrum antibiotics, incentive spirometry, and simple transfusion to Hgb 9.5 g/dL. Over 24 hours, oxygen requirement increases to 8 L/min with SpO2 90%, and CXR shows progression to near-complete bilateral airspace opacification. Hgb is now 10.3 g/dL, and he is tachypneic but not yet intubated. Which is the most appropriate next step?", "options": ["Increase simple transfusions to target Hgb 12 g/dL for better oxygen-carrying capacity", "Initiate exchange transfusion targeting HbS <30%", "Start high-dose corticosteroids to reduce pulmonary inflammation", "Add therapeutic anticoagulation for presumed pulmonary embolism", "Intubate and initiate low tidal-volume ventilation, deferring transfusion changes"], "answer": "B", "answer_index": 1, "explanation": "Worsening hypoxemia, radiographic progression, and clinical deterioration despite initial simple transfusion indicate severe acute chest syndrome, for which exchange transfusion to rapidly lower HbS (<30%) is recommended. Further simple transfusion risks hyperviscosity; steroids are controversial and may increase rebound pain; empiric anticoagulation is not first-line without PE evidence; ventilation may be needed but does not replace disease-modifying exchange.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 22-year-old with HbSS presenting with acute chest syndrome (ACS) that is deteriorating despite initial management with simple transfusion, antibiotics, and supportive care. Key discriminating findings: (1) worsening hypoxemia (O2 requirement 2→8 L/min), (2) radiographic progression to near-complete bilateral opacification, (3) Hgb now 10.3 g/dL after simple transfusion, (4) clinical deterioration over 24 hours. This represents severe/progressive ACS. Option B (exchange transfusion targeting HbS <30%) is the established standard for severe ACS unresponsive to initial therapy, as it rapidly reduces HbS percentage while avoiding hyperviscosity. Option A risks hyperviscosity syndrome with further simple transfusion at Hgb 10.3. Option C (steroids) lacks strong evidence and may worsen rebound pain. Option D (anticoagulation) is not indicated without PE evidence. Option E delays definitive disease-modifying therapy; while intubation may become necessary, exchange transfusion addresses the underlying pathophysiology. The item is medically accurate per current guidelines (ASH, NHLBI) and logically sound with one defensible best answer matching the key. No fix needed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 22-year-old with HbSS presenting with acute chest syndrome (ACS) that is deteriorating despite initial management with simple transfusion, antibiotics, and supportive care. Key discriminating findings: (1) worsening hypoxemia (O2 requirement 2→8 L/min), (2) radiographic progression to near-complete bilateral opacification, (3) Hgb now 10.3 g/dL after simple transfusion, (4) clinical deterioration over 24 hours. This represents severe/progressive ACS. Option B (exchange transfusion targeting HbS <30%) is the established standard for severe ACS unresponsive to initial therapy, as it rapidly reduces HbS percentage while avoiding hyperviscosity. Option A risks hyperviscosity syndrome with further simple transfusion at Hgb 10.3. Option C (steroids) lacks strong evidence and may worsen rebound pain. Option D (anticoagulation) is not indicated without PE evidence. Option E delays definitive disease-modifying therapy; while intubation may become necessary, exchange transfusion addresses the underlying pathophysiology. The item is medically accurate per current guidelines (ASH, NHLBI) and logically sound with one defensible best answer matching the key. No fix needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed125-010", "question": "A 58-year-old man with alcohol-related cirrhosis and portal hypertension is admitted with confusion and generalized tonic-clonic seizures. He has been on valproic acid for epilepsy for 5 years without prior complications. Medications include lactulose and spironolactone. Exam: asterixis, disorientation, jaundice, and mild ascites. Labs: Na 130 mmol/L, K 4.2 mmol/L, BUN 10 mg/dL, creatinine 0.7 mg/dL, AST 65 U/L, ALT 40 U/L, total bilirubin 3.8 mg/dL, INR 1.7, ammonia 96 µmol/L. Serum valproate level is therapeutic, but free valproate level is supratherapeutic; serum carnitine is low, and EEG shows triphasic waves without epileptiform activity. Which is the most appropriate antiseizure management strategy?", "options": ["Continue valproic acid but lower the dose and optimize lactulose therapy", "Discontinue valproic acid and start levetiracetam with IV L-carnitine supplementation", "Switch valproic acid to phenytoin with aggressive albumin replacement", "Add topiramate to valproic acid to improve seizure control", "Continue valproic acid and start rifaximin to reduce ammonia"], "answer": "B", "answer_index": 1, "explanation": "He has cirrhosis with hyperammonemic encephalopathy and high free valproate, consistent with valproate-induced hyperammonemic encephalopathy exacerbated by liver disease and carnitine deficiency; the best approach is to stop valproate, use a non-hepatically metabolized agent such as levetiracetam, and give IV L-carnitine. Dose reduction or adjuncts (lactulose, rifaximin) without discontinuing valproate will not adequately address toxicity; phenytoin is highly protein-bound and hepatically metabolized, and adding topiramate may worsen hyperammonemia.", "generator_model": "gpt-5.1-2025-11-13", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict: Correct best answer. The vignette describes a cirrhotic patient on chronic valproate presenting with confusion, seizures, asterixis, and triphasic waves on EEG. Key discriminating findings: (1) therapeutic total valproate but supratherapeutic free level, (2) low carnitine, (3) elevated ammonia (96 µmol/L), (4) triphasic waves without epileptiform activity, (5) hypoalbuminemia implied by INR 1.7 and cirrhosis. This constellation indicates valproate-induced hyperammonemic encephalopathy (VIAHE), not primary epileptic seizures. In cirrhosis, reduced protein binding elevates free valproate, and valproate inhibits carnitine-dependent mitochondrial fatty acid oxidation, worsening hyperammonemia. The EEG showing triphasic waves (hepatic encephalopathy marker) without epileptiform activity confirms encephalopathy as the primary driver. Option B correctly discontinues the offending agent (valproate), switches to levetiracetam (renally cleared, minimal hepatic metabolism, safe in cirrhosis), and provides IV L-carnitine to reverse valproate's metabolic toxicity. Option A fails to remove the toxin. Option C uses phenytoin (highly protein-bound, hepatically metabolized, problematic in cirrhosis). Option D adds topiramate (can worsen hyperammonemia). Option E continues valproate. No logical flaws or medical inaccuracies; the item tests recognition of VIAHE and appropriate management. Minimal fix: none needed.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a cirrhotic patient on chronic valproate presenting with confusion, seizures, asterixis, and triphasic waves on EEG. Key discriminating findings: (1) therapeutic total valproate but supratherapeutic free level, (2) low carnitine, (3) elevated ammonia (96 µmol/L), (4) triphasic waves without epileptiform activity, (5) hypoalbuminemia implied by INR 1.7 and cirrhosis. This constellation indicates valproate-induced hyperammonemic encephalopathy (VIAHE), not primary epileptic seizures. In cirrhosis, reduced protein binding elevates free valproate, and valproate inhibits carnitine-dependent mitochondrial fatty acid oxidation, worsening hyperammonemia. The EEG showing triphasic waves (hepatic encephalopathy marker) without epileptiform activity confirms encephalopathy as the primary driver. Option B correctly discontinues the offending agent (valproate), switches to levetiracetam (renally cleared, minimal hepatic metabolism, safe in cirrhosis), and provides IV L-carnitine to reverse valproate's metabolic toxicity. Option A fails to remove the toxin. Option C uses phenytoin (highly protein-bound, hepatically metabolized, problematic in cirrhosis). Option D adds topiramate (can worsen hyperammonemia). Option E continues valproate. No logical flaws or medical inaccuracies; the item tests recognition of VIAHE and appropriate management. Minimal fix: none needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]